secwatch.observer — SEC 8-K summary
======================================

Issuer:     SpyGlass Pharma, Inc. (SGP)
CIK:        0001778922
Form:       8-K
Filed at:   2026-08-06T20:16:03+00:00
Accession:  0001778922-26-000044
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

SpyGlass Pharma Q2 net loss $19.9M; cash $234.2M; Phase 3 enrollment on track
-----------------------------------------------------------------------------

- Net loss of $19.9M ($0.59 per share) vs $8.7M ($3.81) in Q2 2025.
- Cash, cash equivalents and short-term investments of $234.2M expected to fund operations through 2028.
- Enrollment in Phase 3 registrational trials of BIM-IOL System on track for completion in 2027.
- BIM-DRS first-in-human trial expected to start in H2 2026.
- Appointed Mike Pinder as VP Marketing; new CPT code for reimbursement pathway.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000044/0001778922-26-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1778922/000177892226000044/sgp-20260806.htm
  HTML page:      https://secwatch.observer/filing/0001778922-26-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer